依达拉奉治疗急性脑梗死的临床研究.doc

1 依达拉奉治疗急性脑梗死的临床研究【摘要】目的:评价依达拉奉治疗发病 72h 内脑梗死的疗效。方法: 100 例 72h 内发病的急性脑梗死患者随机分成两组,两组均用葛根素注射液 g 加入生理盐水中静脉滴注, 治疗组在此基础上再加用依达拉奉 30 mg 加入生理盐水 100 mL 静脉滴注,每日两次, 14d为1 疗程。评价治疗前后神经功能缺失评分和日常生活能力的变化及疗效,监测用药前后肝肾功能的变化。结果:治疗组 14d后神经功能显著改善,与对照组相比差异有显著性( P= ) ,至 21d 差异更显著( P= ) ,治疗组有效率( % ) 明显高于对照组( % ); 治疗组治疗 14d的日常生活能力明显改善, 与对照组相比差异有显著性(P< ) ,至 60d 差异更显著,治疗组有效率( % )明显高于对照组( % ) ,两组患者治疗前后肝肾功能指标无明显改变。结论:依达拉奉治疗急性脑梗死是安全有效的。【关键词】急性脑梗死;依达拉奉;葛根素注射液〔 Abstract 〕 Objective To observe the clinical efficacy and 2 safety of edaravone in treating acute cerebralinfarction. Methods 100 cases with acute cerebral infarction enrolled within 72h of onset were randomized torecEive intravenous injection of EIther edaravone (30 mg in 250 mL of normal saline, bid) plus puerarin injection( g,qd) or contrast therapy (puerarin injection g intravenous injection qd) ina 14-day cycle of the therapy. Theefficasy was assessed using the neurological functional deficit scores by European Stroke Scale (ESS) and activities ofdaily living (ADL). The safety of edaravone was assessed parision of the hepatic and renal fuction before andafter the therepy. Results The ESS score was improved significally in edaravone group than that in contrast groupafter 14 days (P= ) and 21 days (P= ). The ADL was improved significally in edaravone group than thatin control group after 14 da